Development of Src tyrosine kinase substrate binding site inhibitors
{{output}}
The majority of marketed drugs or drug candidates that target protein kinases and which are currently undergoing clinical trials are ATP binding site inhibitors. The process of designing a selective inhibitor as an ATP mimic is challenging, mainly because of t... ...
